The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer

Brief description of study

This study will focus on improving chemotherapy response rates in both primary and metastatic rectal and colorectal cancer. In this study, patients will be divided into two groups to receive different treatments. The first group will be treated with LCRT (locally confined radiation therapy) followed by consolidation FOLFOX (a combination of the chemotherapy drugs Oxaliplatin, 5-FU, and Leucovorin). The second group will receive LCRT followed by consolidated chemotherapy with mFOLFIRINOX, which is a more intense chemotherapy regimen. This approach using stronger chemotherapy has been found to improve the response rates in both primary and metastatic rectal and colorectal cancer.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.